埃索美拉唑在中国上市了吗？

It is a new generation of proton pump inhibitor (PPI), mainly suitable for the treatment of peptic ulcer. Compared with other proton pump inhibitors, esomeprazole has the advantages of shorter course of treatment, more stable efficacy, faster and longer onset of action, and higher HP ulcer eradication rate. It is the latest generation of drugs currently used to treat peptic ulcers. So is esomeprazole available in China? Let’s find out together below.

According to sample hospital sales data from the Southern Institute of Medical Economics, digestive system drug sales exceeded $27 billion in 2012, a year-on-year increase of about 13%. Among them, PPI drugs account for about 70% of the market share. As a new generation of PPI drugs, esomeprazole is in a period of rapid growth. Among the terminal digestive system drug sales in sample hospitals in 2013 by the Southern Medical Research Institute, esomeprazole’s market share reached 3.76%, with the fastest growth rate.

It is understood that currently the only esomeprazole drugs sold on the market in my country are imported varieties from the international pharmaceutical giant AstraZeneca, and there are no other domestic manufacturers. Laimei Pharmaceutical independently developed esomeprazole, breaking the monopoly of foreign pharmaceutical companies. According to my country's current pharmaceutical approval system, Laimei esomeprazole enteric-coated capsules have a three-year monitoring and protection period. In the next three years, Laimei Pharmaceutical will have the exclusive right to produce and sell esomeprazole enteric-coated capsules in my country.

In late June 2014, the national Class 4 new drug esomeprazole enteric-coated capsules (Laimeisu) independently developed by Laimei Pharmaceutical was officially launched on the market, which means that the 15-year research and development of esomeprazole new drug, which started in 1999, was declared successful. It is understood that this new drug is expected to become Laimei Pharmaceutical's largest single product sales revenue in the next few years, with annual sales expected to reach $1 billion, becoming the company's largest profit contributor. With the sales of the immune modulator Urotilin, which will be launched in the second half of the year, the company's exclusive new drug varieties will account for more than half of the sales.